We investigated hemostatic parameters in a prospective study of 16 patients who received bone marrow transplants (BMT). We found a significant rise in the levels of fibrinogen, plasmin-␣ 2 antiplasmin inhibitor complex, tissue-plasminogen activator·plasminogen activator inhibitor complex (t-PA·PAI), von Willebrand factor antigen, and thrombomodulin on day 14 after transplant compared with values before transplant. Protein C and thrombin-antithrombin III levels did not change significantly. No significant changes in prothrombin time ratio, activated partial thromboplastin time, or protein S were detected. Patients who had grades II-IV graft-versus-host disease (GVHD) (n = 6) showed a significantly higher level of t-PA·PAI on day 14 compared with those with grades 0-I GVHD (n = 10) (P = 0.0062). Three patients with grades II-IV GVHD developed thrombotic microangiopathy (TMA) on days 19, 19 and 62. In these patients, we noted significantly lower levels of fibrinogen (P = 0.0383), and significantly higher levels of t-PA·PAI (P = 0.0008) and thrombomodulin (P = 0.0001) on day 14 compared with those patients who did not develop TMA. These results suggest that prothrombotic states and endothelial damage may be caused by the conditioning regimen and/or acute GVHD during BMT; thrombomodulin values on day 14 post BMT may be useful in surveillance for TMA because of endothelial cell injury.
by the conditioning regimen with radio/chemotherapy contributes to veno-occlusive disease (VOD) of the liver, 7, 8 thrombotic microangiopathy (TMA) [9] [10] [11] and graft-versushost disease (GVHD). 12, 13 TMA is a clinical diagnosis which includes hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP); both are characterized by microangiopathic hemolytic anemia, thrombocytopenia, microvascular thrombosis and multiorgan failure.
14 Although several factors may contribute to the onset of this complication, the underlying pathophysiology in TMA consists mainly of microvascular endothelial damage, platelet aggregation, and abnormalities of the coagulation system. Recently it has been reported that thrombomodulin is a useful marker to assess endothelial cell injury not only in patients with HUS/TTP but also in BMT-TMA. 15, 16 In this study, we measured hemostatic parameters, including thrombomodulin, during BMT in a prospective study to find early predictive factors for the development of TMA.
Patients and methods

Patients
Sixteen consecutive patients who received a BMT between October 1994 and February 1996 were analyzed. These patients were transplanted because of hematologic malignancies (four with AML, three with ALL, one with acute undifferentiated leukemia and eight with CML). Twelve patients were at low risk (first remission or first chronic phase of leukemia), and four patients were at high risk (leukemias beyond first remission or chronic phase). Their median age was 29 years (range 16-48 years) (Table 1) . Fifteen patients received marrow transplants from an HLAidentical donor and one from an identical twin. There were nine related donors and seven unrelated donors.
BMT procedures
Four conditioning regimens were employed: thiotepa (TT, 180 mg/m 2 for 2 days), cyclophosphamide (CY, 2250 mg/m 2 for 2 days) and total body irradiation (TBI, 12 Gy) in nine patients; TBI, TT and CY in three patients; busulfan (4 mg/kg for 4 days), cytosine arabinoside (Ara-C 1400 mg/m 2 ϫ 2 for 2 days) and CY in three patients; and TBI, etoposide (1600 mg/m 2 for 1 day), and CY in one patient (Table 1) .
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Thirteen patients received methotrexate (MTX) on days 1, 3, 6 and 11 and cyclosporin A (CsA) (3 mg/kg daily as a continuous infusion) for prevention of GVHD. Two patients received CsA only and one patient with an identical twin donor received neither MTX or CsA.
Laboratory methods
Measurement of hemostatic parameters was performed preconditioning and on day 14 after BMT. Prothrombin time ratio (PT ratio), activated partial thromboplastin time (aPTT) and plasma fibrinogen were measured on the Sysmex CA-5000 (TOA, Kobe, Japan) (normal ranges 0.87-1.15 for PT ratio, 25.3-39.3 s for aPTT and 147-325 mg/dl for fibrinogen). Protein C was determined using a latex photometric immunoassay (LPIA) (LPIA ace; DIA-IATRON, Tokyo, Japan) (normal range 70-150%). Protein S was determined using an enzyme immunoassay (EIA) (Asserachrom total protein S; Boehringer Mannheim, Germany) (normal range 65-135%). Thrombin-antithrombin III complex (TAT) was measured using EIA (TAT SRL; SRL, Tokyo, Japan) (normal Ͻ3.0 ng/ml). Plasmin-␣ 2 antiplasmin inhibitor complex (PIC) was determined using LPIA (normal Ͻ0.8 g/ml). Tissue-plasminogen activator·plasminogen activator inhibitor complex (t-PA·PAI) was evaluated by EIA (tPAI-C test; Teijin, Tokyo, Japan) (normal Ͻ17 ng/ml); von Willebrand factor antigen (vWF:Ag) was tested by EIA (Asserachrom vWf) (normal range 50-155%). Thrombomodulin (TM) was measured by EIA (TM Parassera, Fujirebio, Tokyo, Japan) (normal Ͻ4.5 FU/ml).
Criteria for TMA
TMA was diagnosed by the presence of intravascular hemolysis in association with red cell fragmentation on the peripheral blood smear. Hemolysis was defined if the serum LDH was elevated with a decrease in hemoglobin and increased reticulocytes, as well as a drop in the platelet count. Autoimmune hemolytic anemia was excluded by a negative Coombs' test.
Statistical analysis
The results are expressed as mean and standard error. The difference between values pre-conditioning and post-BMT was determined using Student's t-test for paired data. Mean values between groups of patients were evaluated with Student's t-test for unpaired data.
Results
Clinical data
Engraftment of the bone marrow was obtained in all patients. No acute GVHD occurred in five patients. Eleven patients developed acute GVHD between days 8 and 26 after BMT (grade I, five patients; grade II, four patients; grade III, one patient and grade IV, one patient). No patients developed VOD of the liver. Laboratory findings showed no disseminated intravascular coagulation (DIC) on day 14.
There were three patients with TMA with onset on days 19, 19 and 62 (Table 1) . Clinical courses in these patients were as follows: patient 1 developed acute GVHD (grade II) limited to the skin on day 15 after BMT; he received prednisolone. On day 36, the patient presented with macroscopic hematuria caused by adenovirus. He had a highgrade fever, progressive confusion without focal neurologic signs, and renal dysfunction associated with microangiopathy on day 62. At that time, laboratory data revealed a creatinine of 4.3 mg/dl, a LDH of 1075 U/l, a drop in the hemoglobin level from 9.0 to 5.3 g/dl, and a decrease in platelet count from 39 to 6 ϫ 10 9 /l. The CsA level was 280 ng/ml. Hemodialysis with filtration was performed for acute renal failure and TMA, but his condition deteriorated progressively. He developed cytomegalovirus (CMV) pneumonia and died on day 93. In patient 4, hematuria appeared following preconditioning treatment without evidence of viral infection. Skin GVHD developed on day 13 and progressed to grade IV despite treatment with CsA and prednisolone. Massive red cell fragmentation on the peripheral blood smear was seen on day 19. Serum LDH was 1579 U/l, platelet count was 15 ϫ 10 9 /l, and creatinine was 1.9 mg/ml. The serum CsA was evelated to 430 ng/ml. From day 37, FK506 was administered instead of CsA for acute GVHD treatment. The patient developed generalized seizures on day 47. Cranial computed tomography revealed multifocal infarction, and she expired after cardiac arrest on day 51. Patient 8 developed TMA on day 19 post BMT with hemolytic anemia. She had grade II acute GVHD on day 26. On day 35, serum LDH was 1231 U/l and the platelet count was 17 ϫ 10 9 /l. Plasma exchange with freshfrozen plasma was started on day 37, and vitamin E was administered with a subsequent decrease in serum LDH and bilirubin. However, microangiography hemolysis and thrombocytopenia recurred on day 110. In addition, CMV infection developed, followed by multiorgan failure, and she died on day 152.
Changes in hemostatic parameters
The levels of t-PA·PAI in patients treated with non-TBI regimens were higher than those with TBI regimens (43.2 vs 16.8 ng/ml, P = 0.0357).
Fibrinogen, PIC, t-PA·PAI, vWF:Ag, and TM on day 14 after transplant were significantly increased compared with before treatment (Table 2) . PT ratio, aPTT and protein S did not show significant changes between pre-conditioning and day 14 post-BMT. The trend towards a decrease in protein C among all patients on day 14 compared with preconditioning (P = 0.0691) was due to a significant decrease in patients with grades 0-I GVHD (P = 0.0357) (data not Values are expressed as mean Ϯ s.e. BMT = bone marrow transplantation; PT = prothrombin time; aPTT = activated partial thromboplastin time; TAT = thrombin-antithrombin III complex; PIC = plasmin-␣ 2 antiplasmin inhibitor complex; t-PA·PAI = tissue plasminogen activator-plasminogen activator inhibitor complex; vWF:Ag = von Willebrand factor antigen; TM = thrombomodulin. shown). Only t-PA·PAI increased among groups classified by acute GVHD grade (P = 0.0062) ( Table 3) . Hemostatic parameters on day 14 in the three patients who developed TMA were compared to patients without TMA. TAT increased on day 14, especially in patients with TMA, but without statistical significance. We noted significantly lower levels of fibrinogen and higher levels of t-PA·PAI and TM in patients who later developed TMA (Table 4) . TM levels at pre-conditioning, day 0 and day 14 are indicated individually in Figure 1 . A marked increase in TM levels on day 14 was demonstrated in patients with TMA, despite their levels at day 0 being within the normal range. In patients with and without TMA, serum levels of CsA and creatinine on day 14 were not significant (250 ng/ml in TMA vs 313 ng/ml in non-TMA for CsA and 0.63 vs 0.75 mg/dl, respectively, for creatinine).
Discussion
BMT-TMA is a serious complication following BMT. [9] [10] [11] [12] 16 The frequency in this study was 19%, and all patients who developed TMA died. It is likely that the clinical course of our patients was affected by preceding or simultaneous complications of GVHD and/or viral infection. In previous reports of BMT-TMA, 9, 10 there is a wide clinical spectrum from subclinical lesions to fulminant disease; lethal cases often have simultaneous complications such as GVHD or infection. Zeigler et al 10 found many causes of thrombocytopenia in BMT patients; BMT-associated TMA is dependent on finding evidence of microangiopathic hemolytic anemia. We diagnosed BMT-TMA on the appearance of red cell fragmentation, hemolytic anemia and thrombocytopenia. No patients with VOD were observed, and no laboratory findings indicated DIC on day 14. According to the classification by Pettitt and Clark, 9 our three patients had multifactorial fulminant TMA. Although the pathogenesis of BMT-TMA is still not well understood, it is likely that many factors including the conditioning regimen, CsA, GVHD and infection contribute to the onset of TMA.
We found significant hemostatic abnormalites in patients at an early phase post BMT. Others have reported significant declines in protein C and protein S after BMT 17 and decreased protein C during acute GVHD. 18 Gordon et al 19 demonstrated that protein C deficiency correlated with thrombotic complications in patients undergoing BMT. Nevertheless, we detected no significant changes in protein C or protein S, except for decreased protein C levels on day 14 in patients with grades 0-I GVHD. This discrepancy may be influenced by patient heterogeneity in the different studies. Although a low protein C level before conditioning therapy may predispose to VOD, 20 we could not evaluate this relationship because there were no patients with VOD.
In this study, we noted a significant rise in the fibrinogen, PIC, tPA-PAI, vWF:Ag, and TM on day 14 post BMT compared with pre-conditioning. These changes may be caused by the conditioning regimen or by acute GVHD. The marked increase in t-PA·PAI in patients with severe GVHD suggests that endothelial injuries are related to GVHD grade. In previous investigations by Holler et al, 12 endothelial damage during GVHD was the central lesion of microangiopathy on the basis of analysis of hemostatic parameters such as vWF:Ag. They also reported a highly significant association of microangiopathy with severity of acute GVHD and CsA prophylaxis. Furthermore, increased levels of t-PA and PAI were associated with microangiopathy following BMT and increased levels of tumor necrosis factor alpha (TNF␣). 21 Recently, a correlation between TNF␣ level and complications after BMT, especially acute GVHD, has been reported. 22 TNF␣ is involved in endothelial injury and causes increased capillary permeability. Therefore, TNF␣-mediated endothelial cell damage may contribute to the pathogenesis of several complications post-BMT, including GVHD and TMA.
The most telling finding in our study was the increased TM level on day 14 post BMT in patients who later developed TMA. TM is a high-affinity thrombin receptor on the surface of vascular endothelial cells and a cofactor in the activation of protein C. 23 There is a good correlation between TM levels and clinical complications related to endothelial cell injury in septicemia, VOD and GVHD. 16 Increased TM levels in patients with BMT-TMA have been reported by Zeigler et al. 15 They tested a ratio of TM:creatinine to provide a measure of the renal contribution to the TM elevation. We similarly evaluated this ratio in our series. There was no difference bewteen TM and TM:creatinine values among patients with or without TMA. Thus, an influence of renal function was excluded in this study. The level of t-PA·PAI on day 14 may be associated with various factors during BMT; the significant rise of t-PA·PAI on day 14 was seen in patients with non-TBI regimens, severe GVHD and TMA. Moreover, the individual values of t-PA·PAI were normal or already increased on day 0 (data not shown). In contrast, TM levels on day 0 were normal in all patients. Therefore, we believe that TM values are more strongly correlated with TMA than t-PA·PAI.
It has been reported that the severity of acute GVHD and CsA prophylaxis is highly associated with microangiopathy post BMT. 12 Kalhs et al 11 have suggested that the combined use of CsA and corticosteroids following BMT is an important trigger for the development of microangiopathy. They noted increased levels of vWF:Ag in patients who received CsA and corticosteroids compared with CsA and MTX. In particular, patients with severe microangiopathy showed the highest values of vWF:Ag in the CsA and corticosteroids group. Although the mean difference was not significant, vWF:Ag was higher in our patients with TMA, yielding more evidence of endothelial damage in these patients. Two of three patients with TMA in this report received FK506 instead of CsA after the onset of TMA. Adverse effects of FK506 24, 25 may contribute to the progression of TMA.
In conclusion, alterations in hemostatic parameters were more common in the early phase following BMT, although the causes of these abnormalities are unclear. Our results suggest a hypercoagulable, prothrombotic state with endothelial injury induced by conditioning therapy, acute GVHD, and other complications. The measurement of TM levels on day 14 may be useful for early detection of BMT-TMA, although a direct causal relationship between TM and TMA has not been shown. 
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